{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:37:16Z","timestamp":1787063836704,"version":"build-2736575974"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40259-023-00606-5","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:24:50Z","timestamp":1685492690000},"page":"505-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibody\u2013Drug Conjugates in the Treatment of Urothelial Cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Avani M.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Guevara-Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-2090","authenticated-orcid":false,"given":"Rohit K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"606_CR1","unstructured":"Key Statistics for Bladder Cancer. 2022. Updated 1\/12\/2022. https:\/\/www.cancer.org\/cancer\/bladder-cancer\/about\/key-statistics.html. Accessed 13 July 2022."},{"key":"606_CR2","unstructured":"Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Bladder cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 18 June 2022."},{"issue":"10","key":"606_CR3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/iju.13376","volume":"24","author":"J Miyazaki","year":"2017","unstructured":"Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730\u20134. https:\/\/doi.org\/10.1111\/iju.13376.","journal-title":"Int J Urol"},{"issue":"13","key":"606_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"issue":"11","key":"606_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"3","key":"606_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"606_CR7","doi-asserted-by":"publisher","first-page":"e001246","DOI":"10.1136\/jitc-2020-001246","volume":"8","author":"AB Apolo","year":"2020","unstructured":"Apolo AB, Ellerton JA, Infante JR, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8(2):e001246. https:\/\/doi.org\/10.1136\/jitc-2020-001246.","journal-title":"J Immunother Cancer"},{"issue":"7457","key":"606_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138. https:\/\/doi.org\/10.1038\/nature12213.","journal-title":"Nature"},{"issue":"3","key":"606_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540\u201356. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007. (e25).","journal-title":"Cell"},{"issue":"3","key":"606_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.path.2021.05.005","volume":"14","author":"H Al-Ahmadie","year":"2021","unstructured":"Al-Ahmadie H, Netto GJ. Molecular pathology of urothelial carcinoma. Surg Pathol Clin. 2021;14(3):403\u201314. https:\/\/doi.org\/10.1016\/j.path.2021.05.005.","journal-title":"Surg Pathol Clin."},{"key":"606_CR11","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5273","author":"Y Liu","year":"2021","unstructured":"Liu Y, Han X, Li L, et al. Role of Nectin4 protein in cancer (Review). Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5273.","journal-title":"Int J Oncol"},{"issue":"2","key":"606_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93\u2013103. https:\/\/doi.org\/10.1038\/s41585-020-00394-5.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"606_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/CCO.0000000000000532","volume":"31","author":"O Alhalabi","year":"2019","unstructured":"Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 2019;31(3):207\u201315. https:\/\/doi.org\/10.1097\/CCO.0000000000000532.","journal-title":"Curr Opin Oncol"},{"key":"606_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155390","author":"E Tomiyama","year":"2020","unstructured":"Tomiyama E, Fujita K, Rodriguez Pena MDC, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155390.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"606_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/jco.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase i study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041\u20139. https:\/\/doi.org\/10.1200\/jco.19.02044.","journal-title":"J Clin Oncol"},{"issue":"48","key":"606_CR16","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989\u20139006. https:\/\/doi.org\/10.18632\/oncotarget.25615.","journal-title":"Oncotarget"},{"issue":"2","key":"606_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222\u201333. https:\/\/doi.org\/10.1038\/onc.2012.36.","journal-title":"Oncogene"},{"issue":"12","key":"606_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1158\/1541-7786.MCR-11-0241","volume":"9","author":"J Wang","year":"2011","unstructured":"Wang J, Zhang K, Grabowska D, et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res. 2011;9(12):1686\u201395. https:\/\/doi.org\/10.1158\/1541-7786.MCR-11-0241.","journal-title":"Mol Cancer Res"},{"issue":"35","key":"606_CR19","doi-asserted-by":"publisher","first-page":"58642","DOI":"10.18632\/oncotarget.17407","volume":"8","author":"C Avellini","year":"2017","unstructured":"Avellini C, Licini C, Lazzarini R, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642\u201353. https:\/\/doi.org\/10.18632\/oncotarget.17407.","journal-title":"Oncotarget"},{"key":"606_CR20","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.2147\/OTT.S46887","volume":"7","author":"K Klute","year":"2014","unstructured":"Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Oncotargets Ther. 2014;7:2227\u201336. https:\/\/doi.org\/10.2147\/OTT.S46887.","journal-title":"Oncotargets Ther"},{"issue":"3","key":"606_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/BLC-180169","volume":"4","author":"PJ Vlachostergios","year":"2018","unstructured":"Vlachostergios PJ, Jakubowski CD, Niaz MJ, et al. Antibody-drug conjugates in bladder cancer. Bladder Cancer. 2018;4(3):247\u201359. https:\/\/doi.org\/10.3233\/BLC-180169.","journal-title":"Bladder Cancer."},{"issue":"6","key":"606_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","volume":"12","author":"A Nagayama","year":"2017","unstructured":"Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719\u201339. https:\/\/doi.org\/10.1007\/s11523-017-0535-0.","journal-title":"Target Oncol"},{"issue":"13","key":"606_CR23","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244\u201354. https:\/\/doi.org\/10.1200\/JCO.2001.19.13.3244.","journal-title":"J Clin Oncol"},{"issue":"4","key":"606_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4111\/icu.20220061","volume":"63","author":"JH Kim","year":"2022","unstructured":"Kim, J. H., & Chang, I. H. (2022). A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and clinical urology, 63(4), 373\u2013384. https:\/\/doi.org\/10.4111\/icu.20220061","journal-title":"Investig Clin Urol."},{"issue":"7","key":"606_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14737140.2020.1782201","volume":"20","author":"M Lattanzi","year":"2020","unstructured":"Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther. 2020;20(7):551\u201361. https:\/\/doi.org\/10.1080\/14737140.2020.1782201.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"606_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.Mcr-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody\u2013drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-19-0582.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"606_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clgc.2020.11.006","volume":"19","author":"M Abel","year":"2021","unstructured":"Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A. The evolving landscape of antibody-drug conjugates for urothelial carcinoma. Clin Genitourin Cancer. 2021;19(3):183\u201393. https:\/\/doi.org\/10.1016\/j.clgc.2020.11.006.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"606_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015\u201335. https:\/\/doi.org\/10.1007\/s12325-017-0519-6.","journal-title":"Adv Ther"},{"issue":"29","key":"606_CR29","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/jco.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600. https:\/\/doi.org\/10.1200\/jco.19.01140.","journal-title":"J Clin Oncol"},{"issue":"12","key":"606_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"issue":"6","key":"606_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(21)00094-2.","journal-title":"Lancet Oncol"},{"key":"606_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/DDDT.S240854","volume":"15","author":"M Moussa","year":"2021","unstructured":"Moussa M, Papatsoris A, Abou Chakra M, Dellis A. Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date. Drug Des Dev Ther. 2021;15:453\u201362. https:\/\/doi.org\/10.2147\/DDDT.S240854.","journal-title":"Drug Des Dev Ther"},{"key":"606_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","volume":"102","author":"HP Gerber","year":"2016","unstructured":"Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2015.12.008.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"606_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P Muller","year":"2014","unstructured":"Muller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741\u201355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0198.","journal-title":"Cancer Immunol Res"},{"issue":"315","key":"606_CR35","doi-asserted-by":"publisher","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P M\u00fcller","year":"2015","unstructured":"M\u00fcller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci Transl Med. 2015;7(315):315ra188. https:\/\/doi.org\/10.1126\/scitranslmed.aac4925.","journal-title":"Sci Transl Med."},{"issue":"6_suppl","key":"606_CR36","doi-asserted-by":"publisher","first-page":"TPS589","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS589","volume":"40","author":"MSVD Heijden","year":"2022","unstructured":"Heijden MSVD, Gupta S, Galsky MD, et al. Study EV-302: a two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress). J Clin Oncol. 2022;40(6_suppl):TPS589. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS589.","journal-title":"J Clin Oncol"},{"key":"606_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01643","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.22.01643.","journal-title":"J Clin Oncol"},{"key":"606_CR38","doi-asserted-by":"crossref","unstructured":"J.E. Rosenberg MM, C. Ramamurthy, N. Mar, R.R. McKay, T. Friedlander, C. Ferrario, S. Bracarda, et al. LBA73-Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urotherlial carcinoma (la\/mUC). Presented at: ESMO; 12 Sep 2022 2022; Session Proffered Paper session 2: GU tumours, non-prostate.","DOI":"10.1016\/j.annonc.2022.08.079"},{"key":"606_CR39","doi-asserted-by":"publisher","first-page":"539527","DOI":"10.3389\/fonc.2020.539527","volume":"10","author":"M Peng","year":"2020","unstructured":"Peng M, Xiao D, Bu Y, et al. Novel combination therapies for the treatment of bladder cancer. Front Oncol. 2020;10:539527. https:\/\/doi.org\/10.3389\/fonc.2020.539527.","journal-title":"Front Oncol"},{"issue":"6_suppl","key":"606_CR40","doi-asserted-by":"publisher","first-page":"TPS507","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS507","volume":"39","author":"MD Galsky","year":"2021","unstructured":"Galsky MD, Necchi A, Shore ND, et al. KEYNOTE-905\/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39(6_suppl):TPS507. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.TPS507.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"606_CR41","doi-asserted-by":"publisher","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","volume":"39","author":"CJ Hoimes","year":"2021","unstructured":"Hoimes CJ, Bedke J, Loriot Y, et al. KEYNOTE-B15\/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39(15_suppl):TPS4587. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS4587.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"606_CR42","doi-asserted-by":"publisher","first-page":"TPS587","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS587","volume":"40","author":"CJ Hoimes","year":"2022","unstructured":"Hoimes CJ, Flaig TW, Srinivas S, et al. Study EV-103 cohort L: evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress). J Clin Oncol. 2022;40(6_suppl):TPS587. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS587.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"606_CR43","doi-asserted-by":"publisher","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles T, Drakaki A, Teoh JY-C, et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). J Clin Oncol. 2022;40(6_suppl):TPS579. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS579.","journal-title":"J Clin Oncol"},{"issue":"6","key":"606_CR44","doi-asserted-by":"publisher","first-page":"TPS589","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS589","volume":"40","author":"MS Van Der Heijden","year":"2022","unstructured":"Van Der Heijden MS, Gupta S, Galsky MD, et al. Study EV-302: a two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress). J Clin Oncol. 2022;40(6):TPS589. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS589.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"606_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/JCO.2022.40.6_suppl.435","volume":"40","author":"DP Petrylak","year":"2022","unstructured":"Petrylak DP, Flaig TW, Mar N, et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. J Clin Oncol. 2022;40(6_suppl):435\u2013435. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.435.","journal-title":"J Clin Oncol"},{"issue":"1","key":"606_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00428-022-03328-1","volume":"481","author":"S Garczyk","year":"2022","unstructured":"Garczyk S, Degener S, Bischoff F, et al. Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. Virchows Arch. 2022;481(1):83\u201392. https:\/\/doi.org\/10.1007\/s00428-022-03328-1.","journal-title":"Virchows Arch"},{"key":"606_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050803","author":"A Ungaro","year":"2022","unstructured":"Ungaro A, Tucci M, Audisio A, et al. Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050803.","journal-title":"Cells"},{"issue":"7_suppl","key":"606_CR48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2019.37.7_suppl.354","volume":"37","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Faltas BM, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I\/II study. J Clin Oncol. 2019;37(7_suppl):354\u2013354. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.354.","journal-title":"J Clin Oncol"},{"issue":"22","key":"606_CR49","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/jco.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase ii open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385. https:\/\/doi.org\/10.1200\/jco.20.03489.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"606_CR50","doi-asserted-by":"publisher","first-page":"TPS498","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS498","volume":"39","author":"P Grivas","year":"2021","unstructured":"Grivas P, Tagawa ST, Bellmunt J, et al. TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J Clin Oncol. 2021;39(6_suppl):TPS498. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.TPS498.","journal-title":"J Clin Oncol"},{"key":"606_CR51","doi-asserted-by":"crossref","unstructured":"Petrylak DP, Tagawa, S.T., Jain, R.K. et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial carcinoma (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Presented at: 2023 ASCO GU Cancers Symposium; 2023; San Francisco. Session Urothlial Carcinoma , Therapeutics.","DOI":"10.1200\/JCO.2023.41.6_suppl.520"},{"key":"606_CR52","doi-asserted-by":"crossref","unstructured":"Grivas P, Poussel D, Park CH et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. Presented at: 2023 ASCO GU Symposium; 2023; San Francisco. Session Poster Session B: Prostate Cancer and Urothelial Carcinoma.","DOI":"10.1200\/JCO.2023.41.6_suppl.518"},{"issue":"6_suppl","key":"606_CR53","doi-asserted-by":"publisher","first-page":"TPS581","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS581","volume":"40","author":"ST Tagawa","year":"2022","unstructured":"Tagawa ST, Grivas P, Petrylak DP, et al. TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-na\u00efve patients (pts) with metastatic urothelial cancer (mUC). J Clin Oncol. 2022;40(6_suppl):TPS581. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS581.","journal-title":"J Clin Oncol"},{"key":"606_CR54","doi-asserted-by":"crossref","unstructured":"Duran I, Necchi A, Powles T, et al. TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial carcinoma (mUC). 2023.","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS592"},{"key":"606_CR55","doi-asserted-by":"crossref","unstructured":"Koshkin VS, Henderson N, Kilari D, et al. Enfortumab vedotin (EV) with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). Presented at: 2023 ASCO GU Symposium; 2023; San Francisco. Session Poster Session B: Prostate Cancer and Urothelial Carcinoma.","DOI":"10.1200\/JCO.2023.41.6_suppl.514"},{"key":"606_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005","author":"J Chou","year":"2022","unstructured":"Chou J, Trepka K, Sjostrom M, et al. TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant Cells. Eur Urol Oncol. 2022. https:\/\/doi.org\/10.1016\/j.euo.2021.11.005.","journal-title":"Eur Urol Oncol"},{"key":"606_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.01.004","author":"C Labaki","year":"2022","unstructured":"Labaki C, Bakouny Z, Sonpavde G, Choueiri TK, Van Allen EM. Towards a better understanding of antibody-drug conjugates in urothelial carcinoma. Eur Urol Oncol. 2022. https:\/\/doi.org\/10.1016\/j.euo.2022.01.004.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"606_CR58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med"},{"issue":"6","key":"606_CR59","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1200\/JCO.2021.39.6_suppl.458","volume":"39","author":"M Teo","year":"2021","unstructured":"Teo M, Ratna N, Regazzi A, Zimmerman D, McHugh D. Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma. J Clin Oncol. 2021;39(6):458.","journal-title":"J Clin Oncol"},{"issue":"2","key":"606_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/bco2.125","volume":"3","author":"E Adib","year":"2022","unstructured":"Adib E, El Zarif T, Jain RK, et al. FGFR2\/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass. 2022;3(2):169\u201372. https:\/\/doi.org\/10.1002\/bco2.125.","journal-title":"BJUI Compass."},{"issue":"18","key":"606_CR61","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu CE, Sjostrom M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021;27(18):5123\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4175.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"606_CR62","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"key":"606_CR63","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1200\/JCO.2020.38.6_suppl.546","volume":"38","author":"J Hoffman-Censits","year":"2020","unstructured":"Hoffman-Censits J, Choi W, Lombardo K, Hahn N, McConkey D, McGuire B. Expression of nectin-4 in bladder cancer with variant histology. J Clin Oncol. 2020;38:546\u2013546. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.546.","journal-title":"J Clin Oncol"},{"key":"606_CR64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764","author":"N Klumper","year":"2022","unstructured":"Klumper N, Ralser DJ, Ellinger J, et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1764.","journal-title":"Clin Cancer Res"},{"key":"606_CR65","doi-asserted-by":"crossref","unstructured":"Jindal T, Kilari, D., Alhalabi, O., et al. Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Presented at: 2023 ASCO GU Cancers Symposium; 2023; San Fransciso. Session Poster Session B: Prostate Cancer and Urothelial Carcinoma.","DOI":"10.1200\/JCO.2023.41.6_suppl.450"},{"key":"606_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","volume":"49","author":"E Vlachou","year":"2023","unstructured":"Vlachou E, Matoso A, McConkey D, et al. Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature. Eur Urol Open Sci. 2023;49:100\u20133. https:\/\/doi.org\/10.1016\/j.euros.2023.01.002.","journal-title":"Eur Urol Open Sci."},{"issue":"17","key":"606_CR67","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3321.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"606_CR68","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002.","journal-title":"Ann Oncol"},{"key":"606_CR69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/B978-0-12-822028-3.00006-6","volume-title":"Immunotherapy in resistant cancer: from the lab bench work to its clinical perspectives","author":"M Segovia-Mendoza","year":"2021","unstructured":"Segovia-Mendoza M, Lemini C, Garc\u00eda-Becerra R, Morales-Montor J. Chapter 2\u2014immunoconjugates as immune canoes to kill breast cancer cells. In: Morales-Montor J, Segovia-Mendoza M, editors. Immunotherapy in resistant cancer: from the lab bench work to its clinical perspectives. Academic Press: Cambridge; 2021. p. 11\u201331."},{"issue":"6","key":"606_CR70","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/1535-7163.MCT-15-0570","volume":"15","author":"K Morrison","year":"2016","unstructured":"Morrison K, Challita-Eid PM, Raitano A, et al. Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker. Mol Cancer Ther. 2016;15(6):1301\u201310. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0570.","journal-title":"Mol Cancer Ther"},{"key":"606_CR71","doi-asserted-by":"crossref","unstructured":"Petrylak D, Sonpavde G, George S, Morgans AK, Eigl BJ, Picus J, et al. Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Presented at: ESMO. 2016. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)44408-6\/fulltext. Accessed 01 Oct 2016.","DOI":"10.1093\/annonc\/mdw373.08"},{"issue":"2","key":"606_CR72","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","volume":"60","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60(2):350\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.035.","journal-title":"Eur Urol"},{"issue":"1","key":"606_CR73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157\u201364. https:\/\/doi.org\/10.1007\/s10555-015-9552-6.","journal-title":"Cancer Metastasis Rev"},{"key":"606_CR74","doi-asserted-by":"crossref","unstructured":"Koshkin VS, Boyiddle C, Schwartz N et al. Systemic literature review and testing of HER2 status in urothelial carcinoma (UC). Presented at: 2023 ASCO GU Cancers Symposium; 2023; San Francisco. Session Poster Session B: Prostate Cancer and Urothelial Carcinoma.","DOI":"10.1200\/JCO.2023.41.6_suppl.556"},{"key":"606_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012659","author":"V Albarran","year":"2022","unstructured":"Albarran V, Rosero DI, Chamorro J, et al. Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012659.","journal-title":"Int J Mol Sci"},{"key":"606_CR76","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","volume":"104","author":"G Patelli","year":"2022","unstructured":"Patelli G, Zeppellini A, Spina F, et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives. Cancer Treat Rev. 2022;104:102351.","journal-title":"Cancer Treat Rev"},{"issue":"15_suppl","key":"606_CR77","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1200\/JCO.2018.36.15_suppl.2502","volume":"36","author":"BT Li","year":"2018","unstructured":"Li BT, Makker V, Buonocore DJ, et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol. 2018;36(15_suppl):2502\u20132502. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.2502.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"606_CR78","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.2022.40.6_suppl.438","volume":"40","author":"MD Galsky","year":"2022","unstructured":"Galsky MD, Conte GD, Foti S, et al. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol. 2022;40(6_suppl):438\u2013438. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.438.","journal-title":"J Clin Oncol"},{"key":"606_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020183","author":"B Biri-Kovacs","year":"2020","unstructured":"Biri-Kovacs B, Adorjan A, Szabo I, Szeder B, Bosze S, Mezo G. Structure-activity relationship of her2 receptor targeting peptide and its derivatives in targeted tumor therapy. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10020183.","journal-title":"Biomolecules"},{"issue":"16_suppl","key":"606_CR80","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2022.40.16_suppl.4520","volume":"40","author":"X Sheng","year":"2022","unstructured":"Sheng X, He Z, Shi Y, et al. RC48-ADC for metastatic urothelial carcinoma with HER2-positive: combined analysis of RC48-C005 and RC48-C009 trials. J Clin Oncol. 2022;40(16_suppl):4520\u20134520. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4520.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"606_CR81","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1200\/JCO.2022.40.16_suppl.4518","volume":"40","author":"X Sheng","year":"2022","unstructured":"Sheng X, Zhou L, He Z, et al. Preliminary results of a phase Ib\/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2022;40(16_suppl):4518\u20134518. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4518.","journal-title":"J Clin Oncol"},{"key":"606_CR82","doi-asserted-by":"crossref","unstructured":"Powles T, Yu EY, Iyer G, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). Presented at: 2023 ASCO GU Cancers Symposium; 2023; San Francisco. Session Trials in Progress Poster Session B: Urothelial Carcinoma.","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594"},{"issue":"3","key":"606_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(3):383\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(18)30859-3.","journal-title":"Lancet Oncol"},{"key":"606_CR84","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/DDDT.S14071","volume":"4","author":"M Kowalski","year":"2010","unstructured":"Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Dev Ther. 2010;4:313\u201320. https:\/\/doi.org\/10.2147\/DDDT.S14071.","journal-title":"Drug Des Dev Ther"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00606-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T08:44:45Z","timestamp":1687423485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00606-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00606-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"8 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors whose names are listed immediately below report the following details of affiliation or involvement in an organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this manuscript. Avani M Singh, Jose A Guevara-Patino, and Xuefeng Wang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Roger Li: Research Support: Predicine; Veracyte; CG Oncology; Valar labs. Clinical Trial Protocol Committee: CG Oncology. Scientific Advisor\/Consultant: BMS, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence. Honoraria: SAI MedPartners, Solstice Health Communications, UroToday. Guru Sonpavde: Advisory Board: BMS, Genentech,\u00a0EMD Serono, Merck, Sanofi, Seattle Genetics\/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly\/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV, Vial. Consultant\/scientific advisory board (SAB):\u00a0Suba Therapeutics. Research support\u00a0to institution:\u00a0Sanofi\u00a0(iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric. Speaker\u00a0and travel costs:\u00a0BIO\u2014INFORMA\u00c7\u00c3O BRASILEIRA DE ONCOLOGIA Ltda. Data safety monitoring committee honorarium: Mereo. Employment:\u00a0Spouse employed by Myriad. Rohit K Jain: Advisory Board:\u00a0BMS, EMD Serono, Seattle Genetics\/Astellas,\u00a0Gilead. Consultant\/scientific review committee member:\u00a0NCCN. Research support\u00a0to institution: Gilead, BMS. Speaker\u00a0bureau:\u00a0Seattle Genetics, Gilead. Honorarium:\u00a0Dava Oncology","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AMS and RKJ contributed equally to the writing of the manuscript. JAG-P, XW, RL, and GS each provided feedback on the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}